William F Symmans

William F Symmans

UNVERIFIED PROFILE

Are you William F Symmans?   Register this Author

Register author
William F Symmans

William F Symmans

Publications by authors named "William F Symmans"

Are you William F Symmans?   Register this Author

19Publications

656Reads

12Profile Views

Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer.

Breast Cancer Res Treat 2018 Sep 1;171(2):283-293. Epub 2018 Jun 1.

Departments of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-4835-6DOI Listing
September 2018

Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.

Mol Cell 2018 08;71(4):606-620.e7

Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Graduate School of Biomedical Sciences, University of Texas Health Science Center, Houston, TX 77030, USA; Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung 404, Taiwan; Department of Biotechnology, Asia University, Taichung 413, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10972765183059
Publisher Site
http://dx.doi.org/10.1016/j.molcel.2018.07.030DOI Listing
August 2018

Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer.

Hum Pathol 2018 07 22;77:121-129. Epub 2018 Apr 22.

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2018.04.002DOI Listing
July 2018

Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.

PLoS Med 2016 Dec 13;13(12):e1002193. Epub 2016 Dec 13.

Department of Medicine, Yale School of Medicine, Yale University, New Haven, Connecticut, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pmed.1002193DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154510PMC
December 2016

FOXC2 regulates the G2/M transition of stem cell-rich breast cancer cells and sensitizes them to PLK1 inhibition.

Sci Rep 2016 Apr 11;6:23070. Epub 2016 Apr 11.

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Centre, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep23070DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827390PMC
April 2016

Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

J Clin Oncol 2015 Aug 20;33(24):2695-704. Epub 2015 Jul 20.

Catherine Van Poznak and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Robert C. Bast, Ana M. Gonzalez-Angulo, and William F. Symmans, University of Texas MD Anderson Cancer Center, Houston; Robert G. Mennel, Texas Oncology, Dallas, TX; Massimo Cristofanilli, Thomas Jefferson University-Kimmel Cancer Center, Philadelphia, PA; Matthew P. Goetz and Minetta C. Liu, Mayo Clinic, Rochester, MN; David G. Hicks, University of Rochester Medical Center, Rochester, NY; Elizabeth G. Hill, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC; Wanda Lucas, Georgetown University, Washington, DC; Ingrid A. Mayer, Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center, Nashville, TN; and Lyndsay N. Harris, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.1459DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478102PMC
August 2015

Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer.

Breast Cancer Res 2012 May 4;14(3):R72. Epub 2012 May 4.

Department of Radiation Oncology, 1515 Holcombe Blvd,, University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.

View Article

Download full-text PDF

Source
http://breast-cancer-research.biomedcentral.com/articles/10.
Publisher Site
http://dx.doi.org/10.1186/bcr3181DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446334PMC
May 2012

Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer.

J Natl Cancer Inst Monogr 2011 ;2011(43):99-102

Unità di Patologia Mammaria-Breast Cancer Unit, Azienda Instituti Ospitalieri di Cremona, Cremona, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jncimonographs/lgr030DOI Listing
March 2012

Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines.

Breast Cancer Res Treat 2010 Jun 15;121(2):301-9. Epub 2009 Jul 15.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, BO Box 301439, Houston, TX 77030-1439, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-009-0445-7DOI Listing
June 2010

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.

J Clin Oncol 2008 Feb;26(5):814-9

Seattle Cancer Care Alliance, Department of Medicine, 825 Eastlake Ave, EMS G3-200, Seattle, WA 98109-1023, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.15.3510DOI Listing
February 2008

Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience.

Cancer 2007 Sep;110(6):1195-200

Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.22895DOI Listing
September 2007

Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells.

Lab Invest 2005 Nov;85(11):1357-67

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/labinvest.3700339DOI Listing
November 2005